Dividends & Buybacks ·
Liminatus Pharma, Inc. held its 2026 Annual Meeting of Stockholders on August 3, 2026, where shareholders approved the…
LIMNLiminatus Pharma, Inc.
Liminatus Pharma, Inc. held its 2026 Annual Meeting of Stockholders on August 3, 2026, where shareholders approved the ratification of Withum Smith+Brown PC as independent auditor and elected Nicholas Fernandez and Dr. Ji Yeon Baek to the Board. Crucially, stockholders authorized the Board to implement a reverse stock split at a ratio of up to 1-for-50 shares to satisfy Nasdaq listing requirements. The company operates in the biopharmaceutical industry.